The CTD² Network and Cancer Systems Biology Consortium organized a virtual symposium series titled “Multidisciplinary Approaches to Understand Cancer Treatment Resistance”. Please join us on 11/16, 11/17, 12/2, 12/16, and 12/17. Click here to view the registration website.
Publications
Integration of comprehensive molecular characterization and functional genomic studies identifies paralog gene dependencies induced by somatic mutations. Paralog pair, MAGOH and MAGOHB, identified as members of the exon-junction complex was shared between the shRNA and CRISPR datasets.
Natural killer cells derived from human-induced pluripotent stem cells are effective against ovarian cancer in a mouse xenograft model and may provide an off-the-shelf resource for anti-cancer immunotherapy.
UCSF (1) CTD2 scientists developed a quantitative chemoproteomics approach that combines kinase affinity capture with quantitative mass spectrometry. This technique could be used for developing effective combinatorial therapies.
CTD2 sceintists at Columbia University developed a new precision oncology approach, OncoTreat. This approach enables the systematic prioritization of compounds targeting tumor checkpoint dependencies in gastroenteropancreatic neuroendocrine tumors.
Authors identified transcription factor activating protein 4 (TFAP4) as a critical effector of MYCN amplification in neuroblastoma and showed that silencing TFAP4 inhibits MYCN-amplified neuroblastoma cell growth.